Opinion|Videos|August 19, 2024
Patient Access Advocacy for BTK Inhibitors
A panel of specialists discuss patient access advocacy for BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do changes in patient out-of-pocket costs under the IRA influence treatment and sequencing decisions?
- What strategies can healthcare providers use to advocate for patient access to BTK inhibitors?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
2
Novel CLL Therapies Prompt New Treatment Considerations
3
Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD
4
ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC
5
